Ann: Quarterly Activities Report and Appendix 4C, page-3

Based off what I can see in the trading, I think that’s what investors are waiting for before this begins to rerate into phase 1, Walter Reed and FDA phase 2 over the period ahead. But also gives them cash to have a non stop runway and significant rerate that won’t be littered with cap raising risk. With their R&D I would imagine for the complete runway into phase 2 and non dilutive funding coming in as well a 2-3 million dollar raise is coming with a 10 percent discount to a 10 day VWAP which will be an excellent small raise which will see this rerate significantly short term and medium term. If they execute that raise then its game on